TY - JOUR
T1 - Sexually Transmitted Infection Prevalence among Women at Risk for HIV Exposure Initiating Safer Conception Care in Rural, Southwestern Uganda
AU - Chitneni, Pooja
AU - Bwana, Mwebesa Bosco
AU - Owembabazi, Moran
AU - O'Neil, Kasey
AU - Kalyebara, Paul Kato
AU - Muyindike, Winnie
AU - Musinguzi, Nicholas
AU - Bangsberg, David R.
AU - Marrazzo, Jeanne M.
AU - Haberer, Jessica E.
AU - Kaida, Angela
AU - Matthews, Lynn T.
N1 - Funding Information:
Conflict of Interest and Sources of Funding: The authors have no conflicts of interest to disclose. This study is funded through the Doris Duke Charitable Foundation. P.C. received funding from the National Institute of Allergy and Infectious Diseases under award number T32 AI007433 and from the Fogarty International Center and National Institute of Mental Health under award number D43 TW010543, all under the National Institutes of Health. J.E.H. is supported by K24MH114732. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda. Methods We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates. Results Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94). Conclusions We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.
AB - Background Knowledge of sexually transmitted infection (STI) prevalence and risk factors is important to the development of tenofovir-based preexposure prophylaxis (PrEP) and safer conception programming. We introduced STI screening among women at risk for HIV exposure who were participating in a safer conception study in southwestern Uganda. Methods We enrolled 131 HIV-uninfected women, planning for pregnancy with a partner living with HIV or of unknown HIV serostatus (2018-2019). Women were offered comprehensive safer conception counseling, including PrEP. Participants completed interviewer-administered questionnaires detailing sociodemographics and sexual history. We integrated laboratory screening for chlamydia, gonorrhea, trichomoniasis, and syphilis as a substudy to assess STI prevalence. Multivariable logistic regression was used to determine correlates. Results Ninety-four women completed STI screening (72% of enrolled). Median age was 30 (interquartile range, 26-34) years, and 94% chose PrEP as part of safer conception care. Overall, 24% had STIs: 13% chlamydia, 2% gonorrhea, 6% trichomoniasis, 6% syphilis, and 3% ≥2 STI. Sexually transmitted infection prevalence was associated with younger age (adjusted odds ratio [AOR], 0.87; 95% confidence interval [CI], 0.77-0.99), prior stillbirth (AOR, 5.04; 95% CI, 1.12-22.54), and not feeling vulnerable to HIV (AOR, 16.33; 95% CI, 1.12-237.94). Conclusions We describe a 24% curable STI prevalence among women at risk for HIV exposure who were planning for pregnancy. These data highlight the importance of integrating laboratory-based STI screening into safer conception programs to maximize the health of HIV-affected women, children, and families.
UR - http://www.scopus.com/inward/record.url?scp=85088487648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088487648&partnerID=8YFLogxK
U2 - 10.1097/OLQ.0000000000001197
DO - 10.1097/OLQ.0000000000001197
M3 - Article
C2 - 32404858
AN - SCOPUS:85088487648
SN - 0148-5717
VL - 47
SP - E24-E28
JO - Sexually Transmitted Diseases
JF - Sexually Transmitted Diseases
IS - 8
ER -